提醒成功

搜索
产品规范 | |
---|---|
Type | In Vivo - Reseach Grade Antibody |
Host | CHO cells |
catalog# | B00050 |
Application | Flow cytometry, animal model study |
Aliases | Anti-KDR Human Monoclonal Antibody, Ramucirumab Research Grade, Ramucirumab RUO |
Size/Concentration | 1mg/5mg/20mg |
Isotype | Human IgG1 kappa |
Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | Human VEGFR2 |
Formulation | PBS, pH 7.4 |
Description |
---|
What is ramucirumab biosimilar research grade? Research grade Ramucirumab biosimilar uses the same protein sequences as the therapeutic antibody ramucirumab. Ramucirumab, a fully human IgG1 monoclonal antibody and a direct VEGFR2 antagonist, binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis. Kinase insert domain receptor (KDR, a type IV receptor tyrosine kinase, CD309, cluster of differentiation 309, Flk1, Fetal Liver Kinase 1) is the human gene encoding vascular endothelial growth factor receptor 2 (VEGFR-2), which is a VEGF receptor. The Q472H germline KDR genetic variant affects VEGFR-2 phosphorylation and has been found to associate with microvessel density in NSCLC. |
Ramucirumab Biosimilar, Human VEGFR2 Monoclonal Antibody B00050
规格:
- 1mg
- 5mg
- 20mg
数量:
-
+
说明书:


¥1300
-
咨询
-
收藏

